Burosumab - a new drug  to treat  hypophosphatemic rickets

descriptionPublicationkeyboard_double_arrow_right Article 01 Jan 2017Publisher:Discover STM Publishing Ltd.Journal:Sudanese Journal of Paediatrics (issn: 0256-4408,

Copyright policy )

Authors: Stepan Kutilek; Dr. Babiker; Dr. Alenazi;

doi: 10.24911/sjp.2017.2.11

pmid: 29545670

pmc: PMC5845463

Burosumab - a new drug to treat hypophosphatemic rickets

- Summary
- Metrics

Abstract

Burosumab (KRN23) is a fully human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic rickets. A report enclosed in this letter gives a brief review of current knowledge on burosumab therapy.

Related Organizations

Charles University
Czech Republic

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	6
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%